RxDoctor Payments Data

Mubashar Khan, MD

Cardiovascular Disease · Camden, NJNPI 1497175707

Payments from drug & device makers

$24,651in general payments, 2019–2025

Across 395 payments — averaging $62.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$13K
  • Medtronic$3K
  • Boston Scientific$2K
  • Novartis$940
  • Amgen$589
  • Johnson & Johnson$491
  • plus $4K from 34 others

What the payments were for

  • Speaking & faculty fees$12,75052%
  • Travel & lodging$3,12113%
  • Food & beverage$8,40534%
  • Education$3001%
  • Entertainment$750%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$24,651 in reported general payments places this provider in the 85th percentile of 1,006 cardiovascular disease providers in New Jersey.

See all cardiovascular disease providers in New Jersey

Medicare billing

Part B allowed, 2024
$724,597
Medicare patients
2,463
Services billed
19,503

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban392$495,235
EntrestoSacubitril/Valsartan177$210,830
XareltoRivaroxaban140$171,101
Repatha SureclickEvolocumab167$169,157
Praluent PenAlirocumab36$42,328
BrilintaTicagrelor40$31,133
JardianceEmpagliflozin15$19,002
Metoprolol Succinate1,004$15,210
Valsartan462$15,147
VascepaIcosapent Ethyl21$15,075
NexletolBempedoic Acid17$13,077
NexlizetBempedoic Acid/Ezetimibe11$12,741
Repatha SyringeEvolocumab15$12,399
Rosuvastatin Calcium877$10,894
Ranolazine ErRanolazine78$8,528

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$426$495,235392 claims
NovartisEntresto$940$210,830177 claims
Johnson & JohnsonXarelto$491$171,101140 claims
AstraZenecaBrilinta$134$31,13340 claims
Esperion Therapeutics, Inc.Nexletol, Nexlizet$129$25,81728 claims
Boehringer IngelheimJardiance$110$19,00215 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,006 cardiovascular disease providers in New Jersey.

Other cardiovascular disease in Camden

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →